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Abstract
Background: Several staging systems have been developed to evaluate patients with hepatocellular carcinoma
(HCC), including the China Staging System (CS), the American Joint Committee on Cancer (AJCC) tumor-node-metastasis
(TNM) staging system, and seventh edition; the Barcelona Clinic Liver Cancer (BCLC) staging system, and Cancer of the
Liver Italian Program (CLIP) staging system. The optimal staging system for to evaluate patients in China with HCC has not
been determined. This study was designed to determine the optimal staging system for predicting patient prognosis by
comparing the performances of these four staging systems in a cohort of Chinese patients with HCC.
Methods: This study enrolled 307 consecutive Chinese patients with HCC in Shandong Province. The performances of
the CS, TNM, BCLC, and CLIP staging systems were compared and ranked using a concordance index. Predictors of
survival were identified using univariate and multivariate Cox model analyses.
Results: The mean overall survival of the patient cohort was 12.08 ± 11.87 months. Independent predictors of survival
included tumor size, number of lesions, tumor thromboses, cirrhosis, serum albumin level and serum total bilirubin level.
Compared with the other three staging systems, the CS staging system showed optimal performance as an independent
predictor of patient survival. The BCLC staging system showed the poorest performance; its treatment algorithm was not
suitable for patients in this study.
Conclusions: CS was the most suitable staging system for predicting survival of patients with HCC in China.
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Background
Hepatocellular carcinoma (HCC) is the sixth most com-
mon cancer and the third leading cause of cancer deaths
worldwide [1]. Approximately 55 % of patients with HCC
live in China and the 5-year overall survival (OS) rate is
only 7 % [2]. Unlike other solid tumors, the prognosis and
treatment options for patients with HCC depend not only
on the tumor stage but also on residual liver function [3].
Many staging systems that include both the liver cancer
and residual liver function have been developed, including
the Cancer of the Liver Italian Program (CLIP); the Barce-
lona Clinic Liver Cancer (BCLC), the American Joint
Committee on Cancer (AJCC) tumor-node-metastasis
(TNM), seventh edition and the China Staging (CS) sys-
tems [4–8].
Many clinical trials in western countries have evaluated
the staging, natural history and prognosis of patients with
HCC, with highly variable [9, 10]. Despite China having a
greater disease burden than the rest of the world, few stud-
ies have been performed in China. Shandong Province,
located in the east of China, has a high incidence of HCC.
To date, the tumor staging system optimal for evaluating
patients with HCC in Shandong province has not been
determined. This retrospective study compared the perfor-
mances of four staging systems, the CLIP, BCLC, AJCC
TNM 7th edition, and CS staging systems, in patients with
HCC in Shandong Province, China, who were treated at
Qilu Hospital of Shandong University. This study also
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attempted to identify factors independently prognostic of
survival in these patients.
Methods
This study was approved by the institutional ethical
committee at Qilu Hospital of Shandong University. All
patients or their family provided written informed con-
sent for their clinical records to be stored in the hospital
database and used for research.
Patients
Between January 1, 2010, and October 31, 2014, 673 con-
secutive patients diagnosed with liver cancer were seen at
Qilu Hospital of Shandong University. Of these, 366 pa-
tients were excluded, including 152 lost to follow-up, 88
with missing data, 58 with cancer of other organs or tis-
sues metastasis to the liver, 47 diagnosed with intrahepatic
cholangiocellular carcinoma, and 21 diagnosed at other
centers and referred to Qilu Hospital. The remaining 307
patients with HCC were consecutively enrolled and retro-
spectively analyzed (Fig. 1).
Baseline information, including the results of clinical ex-
aminations, laboratory evaluations, imaging modalities (e.g.
computed tomography [CT], magnetic resonance imaging
[MRI] and/or ultrasonography), was collected at the time of
diagnosis. OS was defined the time from the date of initial
diagnosis of HCC to the date of death, last follow-up or the
date of censoring (January 1, 2015), whichever came first.
HCC diagnosis was confirmed by histopathological
examination of surgical samples or cytologic evaluation of
needle biopsy samples (especially if mass less than 2 cm).
Alternatively, a diagnosis of HCC was based on the radio-
logic criteria of the European Association for the Study of
the Liver (EASL) [11, 12]. Based on collected data, all in-
cluded patients were restaged retrospectively according to
the CLIP, BCLC, AJCC TNM seventh edition, and CS sta-
ging systems.
Statistical methods
All patients were followed up until death or January 1,
2015. Continuous variables were expressed as mean ±
standard deviation (SD), and categorical as frequencies
and percentage. Survival outcomes were estimated by the
Kaplan–Meier method and compared by the log-rank test.
Staging systems were ranked using the concordance
index (c-index), which measures the capacity of the dif-
ferent staging systems to stratify patients with different
outcomes: the higher the c-index, the more informative
the model was about patient outcomes.
Independent prognostic factors were identified through
backward stepwise selection in a Cox regression model.
Variables significant (p < 0.05) on univariate analysis were
included in the multivariate Cox proportional hazards
model. Adjusted hazard ratios (HRs) and 95 % confidence
intervals (95 % CIs) were calculated.
All statistical analyses were performed using STATA/SE
version 13.1 software (Stata Corporation, College Station,
TX, USA). All p-values were two-sided, and those less
than 0.05 were considered statistically significant.
Fig. 1 Flow chart of the study
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Table 1 Baseline demographic and clinical characteristics of the
307 patients with hepatocellular carcinoma (Additional files 1 and 2)
Characteristic
Age, years











































Table 1 Baseline demographic and clinical characteristics of the
307 patients with hepatocellular carcinoma (Additional files 1 and 2)
(Continued)
Laboratory values, mean ± SD
Total bilirubin (μmol/l) 24.55 ± 50.93
Albumin (g/l) 38.53 ± 5.78
Prothrombin time (sec) 0.19 ± 0.80
AFP (ng/ml), %
< 400 211 (68.7)
≥ 400 96 (31.3)
Tumor characteristics
Tumor size (mean ± SD, cm) 6.18 ± 4.04
Number of lesions, %
1 200 (65.2)
2–3 29 (9.4)
≥ 4 78 (25.4)
Lobar involvement, %
Unilobar 164 (53.4)




Massive, diffuse 83 (27.0)
Vascular and/or organ invasion, %
No 235 (76.6)
Portal/hepatic vein 52 (16.9)
Other vascular 9 (2.9)









Portal stem vein 26 (8.5)
Inferior vena cava 6 (1.9)
Hepatic vein branches 2 (0.7)
Portal vein branches 16 (5.2)
Vessel 3 (1.0)
Hepatic duct 2 (0.7)
Inferior vena cava branches and






OS, mean ± SD, months 12.08 ± 11.87
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Results
Patient characteristics
Of the 307 patients with HCC included in the study, 252
(82.1 %) were male and 55 (17.9 %) were female, with a
mean age of 55.43 ± 10.69 years. Among the 307 patients
with HCC, 143 (46.6 %) were confirmed by histopatho-
logical examination of surgical samples or cytologic evalu-
ation of needle biopsy samples, that the main tumor
differentiation was intermediate (40.6 %), and 164 (53.4 %)
were diagnosed by the imaging criteria. The most frequent
etiology of underlying liver disease was hepatitis B virus
(HBV) infection (77.8 %), followed by other etiology
(17.6 %), hepatitis C virus (HCV) infection (2.3 %) and al-
coholism (1.6 %); only 0.7 % of patients were infected with
both HBV and HCV. In total, 65.2 % of patients had a sin-
gle tumor, with a mean tumor size of 6.18 ± 4.04 cm; and
77.9 % of patients had underlying Child-Pugh class A liver
function. Regarding treatment modalities, 56.1 % of pa-
tients underwent curative procedures (LR and RFA),
whereas TACE, MWA, systemic treatment and supportive
care were administrated to 18.9 %, 3.9 %, 4.2 %, 16.9 % of
patients, respectively. Of the 307 patients, 120 (39.1 %)
had died by the time of the final analysis (January 1,
Table 2 Tumor staging information of the 307 patients with
hepatocellular carcinoma































Table 3 Univariate analyses of factors independently prognostic of
overall survival in the 307 patients with hepatocellular carcinoma
Variable Coefficient SE P HR 95 % CI
Sex 0.39 0.28 0.156 1.48 0.86–2.54
Age −0.09 0.08 0.293 0.92 0.78–1.08
ECOG PS 0.74 0.10 0.000 2.10 1.74–2.54
Tumor size 0.15 0.02 0.000 1.16 1.12–1.21
Number of lesions 0.58 0.10 0.000 1.78 1.47–2.17
Lobar involvement 1.16 0.20 0.000 3.20 2.18–4.70
Tumor formation 0.70 0.11 0.000 2.01 1.63–2.49
Ascites 0.44 0.10 0.000 1.55 1.27–1.89
Total bilirubin 0.68 0.14 0.000 1.98 1.51–2.60
Albumin −0.10 0.02 0.000 0.91 0.88–0.94
Child-Pugh Grade 0.86 0.16 0.000 2.37 1.72–3.25
alpha-fetoprotein 0.72 0.18 0.000 2.05 1.43–2.94
hepatitis B virus −0.37 0.21 0.081 0.69 0.46–1.05
hepatitis C virus −0.55 0.59 0.347 0.58 0.18–1.82
Alcoholism 0.53 0.59 0.366 1.70 0.54–5.36
Other 0.42 0.23 0.066 1.53 0.97–2.39
Lymph node metastasis 0.81 0.21 0.000 2.26 1.48–3.43
Distant metastasis 1.37 0.22 0.000 3.93 2.56–6.05
Tumor thromboses 1.31 0.20 0.000 3.71 2.50–5.50
Portal hypertension 0.30 0.22 0.173 1.35 0.88–2.09
Cirrhosis −0.80 0.18 0.000 0.45 0.31–0.64
Vascular/organ invasion
Portal/hepatic vein 1.31 0.21 0.000 3.72 2.47–5.60
Others 0.79 0.33 0.015 2.21 1.17–4.18
Table 4 Multivariate analysis of factors prognostic of overall
survival in the 307 patients with hepatocellular carcinoma
Variables Coefficient SE P HR 95 % CI
Cirrhosis −0.56 0.21 0.008 0.57 0.38–0.87
Tumor size 0.11 0.02 0.000 1.12 1.07–1.17
Number of lesions 0.36 0.11 0.001 1.44 1.16–1.79
Total bilirubin 0.56 0.16 0.000 1.74 1.28–2.37
Albumin −0.04 0.02 0.019 0.96 0.93–0.99
Tumor thromboses 0.70 0.22 0.001 2.01 1.31–3.09
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2015). The mean OS was 12.08 ± 11.87 months (Table 1;
Additional files 1 and 2).
Patients were classified into stage groups according to
the four staging systems. According to the BCLC staging
system, 63.8 % of referred patients had advanced stage
tumor stages. In contrast, the different AJCC TNM
stages were more evenly distributed, and 96.7 % of pa-
tients had CLIP scores ≤ 4. According to the CS staging
system, 29.7, 37.1, and 33.2 % of patients had stages I, II,
and III disease, respectively (Table 2).
Baseline predictors of survival
Univariate analysis showed that Child-Pugh grade, tumor
size and number, serum total bilirubin and AFP concen-
trations, tumor thromboses, and cirrhosis were signifi-
cantly associated with OS (Table 3). Multivariate analysis
found that tumor size, number of lesions; serum total bili-
rubin level and tumor thromboses were the most accurate
independent predictors of OS (p ≤ 0.001 each). In addition,
cirrhosis and albumin were also predictive of reduced OS
(Table 4).
Fig. 2 Kaplan–Meier analysis of overall survival in 307 patients with hepatocellular carcinoma stratified according to the Cancer of the Liver Italian
Program (CLIP) staging system. All differences between groups wee statistically significant (p < 0.001)
Fig. 3 Kaplan–Meier analysis of overall survival in 307 patients with hepatocellular carcinoma stratified according to the Barcelona Clinic Liver
Cancer staging system. All differences between groups were statistically significant (p < 0.001)
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Survival comparisons among staging groups
Survival curves were generated by Kaplan–Meier method
for each of the four staging systems. Stage groupings of all
four staging systems were significantly predictive of OS
(p < 0.001 each), although some overlapping of survival
curves was observed (Figs. 2, 3, 4 and 5).
Ranking of discriminatory ability of staging system
The prognostic ability of the different staging systems was
compared by calculating the c-index of each. The CS
staging system had the highest c-index (0.75; 95 % CI,
0.71–0.80), followed by CLIP (0.74; 95%CI, 0.69–0.79), the
AJCC TNM seventh edition (0.70; 95 % CI, 0.65–0.75),
and BCLC (0.69; 95 % CI, 0.65–0.73) staging systems.
There was a significant difference between prognostic
ability of the CS staging system compared with BCLC
staging system (p = 0.031). However, it was no statisti-
cally difference among the others (CS compared with
CLIP, p = 0.130; CS compared with the AJCC TNM sev-
enth edition, p = 0.746; CLIP compared with the AJCC
Fig. 4 Kaplan–Meier analysis of overall survival in 307 patients with hepatocellular carcinoma stratified according to the AJCC TNM seventh
edition staging system. All differences between groups were statistically significant (p < 0.001)
Fig. 5 Kaplan–Meier analysis of overall survival in 307 patients with hepatocellular carcinoma stratified according to the Chinese staging system.
All differences between groups were statistically significant (p < 0.001)
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TNM seventh edition, p = 0.243; CLIP compared with
BCLC, p = 0.661; the AJCC TNM seventh edition com-
pared with BCLC, p = 0.080) (Table 5).
Discussion
The predominant etiology of HCC in patients in Shandong
Province China was HBV infection. This study of factors
independently prognostic of OS in this population found
that tumor extent (e.g. tumor size, number of liver lesions,
and tumor thromboses), hepatic function (serum total bili-
rubin concentration and serum albumin level), cirrhosis
were independent baseline predictors of OS. Of this pa-
tient population, 68.4 % had underlying cirrhosis, which
was strongly associated with OS, and 70–80 % showed
histological evidence of liver cirrhosis. AFP was again of
limited use in this study, because it was proven to be both
not sensitive enough to identify early stage HCC and not
specific enough to avoid unnecessary recall procedures, so
AFP test has been dropped from the latest Western guide-
line for the clinical diagnosis of HCC [11–13]. We also
founded that serum total bilirubin concentration, serum
albumin level and greater tumor extent were related to
poor prognosis variables, indicating that the long-term
survival of patients with HCC was associated not only with
the tumor but with liver function [3, 14–16].
CS was a new staging system proposed by Chinese Soci-
ety of Liver Cancer (CSLC) for the patients with hepato-
cellular carcinoma and was initially launched in 2001. The
CS staging system combined hepatic function, as defined
by Child-Pugh classification, and tumor extent, as defined
by adjusted TNM stage, that the parameters included
tumor size and tumor location, thrombosis (portal vein, in-
ferior vena cava and biliary duct), lymph node metastasis,
distant metastasis and the Child-Pugh classification [8]. It
classified stages of disease into six subgroups, from Ia to
IIIb (Table 6). This study found that the CS staging system
had the highest c-index and there was a significant differ-
ence between prognostic ability of the CS staging system
compared with BCLC staging system (p = 0.031). So, the
CS staging system was optimal in distinguishing survival
categories in patients with HCC in Shandong Province,
China. The CS staging system was the most prognostic in
our cohort because it included the independent predictors
of survival we had identified. These included serum
concentration of total bilirubin and serum albumin level,
parameters of Child-Pugh grade, which can reflect the re-
sidual hepatic function of the patients with HCC; and
tumor stage (tumor size, portal vein thromboses, and
number of liver lesions). In contrast, the BCLC staging sys-
tem showed the poorest performance, despite its having
been viewed as the standard classification that is used for
trial design and clinical management of patients with HCC
[17]. Several reasons may explain the unsuitability of the
BCLC staging system for Chinese patients with HCC. First,
studies have shown that the performance of the BCLC sta-
ging system may be better in patients with early than late
stage disease [18, 19]. However, 63.8 % of the patients in
our study had advanced stage disease (BCLC stage C), lim-
iting the discriminatory ability of BCLC staging. Second,
the natural history of HCC may vary by underlying eti-
ology. The primary cause of HCC in western countries is
HCV infection, whereas the primary cause of HCC in our
population was HBV infection (77.8 %). Therefore, the
ability of BCLC staging to stratify Asian patients with
HBV-associated HCC remains unclear [19, 20].
This study had several potential limitations. First, it
was retrospective in design. Moreover, 152 patients were
lost to follow up and data were missing for 88. However,
Table 5 Ranking of staging systems by concordance indices in
patients with hepatocellular carcinoma
Rank System C-index 95 % CI
1 CS 0.75 0.71–0.80
2 CLIP 0.74 0.69–0.79
3 TNMa 0.70 0.65–0.75
4 BCLC 0.69 0.65–0.73
aSeventh edition
Table 6 The classification criteria of China staging system
Stage Tumor size (cm) and location Thrombosis N M Child-Pugh score
Ia single, ≤ 3 absent absent absent A
Ib unilobar, ≤ 5 absent absent absent A
IIa unilobar, ≤ 10; or bilobar, ≤ 5 absent absent absent A
IIb unilobar, >10; or bilobar, > 5; any absent; portal vein, or inferior
vena cava, or biliary duct branches
absent absent
absent absent A or B
IIIa any; portal vein, or inferior vena cava,
or biliary duct stem;
any any A or B
any; any; present any
any any any present
IIIb any any any any C
N lymph node metastasis, M distant metastasis
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many Chinese people live in the countryside, making
communication difficult. Thus, there may have been po-
tential bias in patient selection. Secondly, this was a single-
center study involving patients admitted consecutively to
Qilu Hospital of Shandong University for treatment. How-
ever, our study had several strengths. Complete data were
obtained from a large number of patients. Moreover, the
follow-up period was relatively long, and the epidemio-
logical characteristics of our cohort were consistent with
those reported in other studies of Chinese patients with
HCC [20, 21].
Conclusions
Of the four HCC staging systems evaluated, the CS staging
system was the most informative in predicting survival for
patients with HCC in Shandong Province. The poor per-
formance of the BCLC staging system in this cohort sug-
gests its unsuitability for evaluating Chinese patients with
HCC. We also found that tumor size, number of lesions,
tumor thromboses, serum total bilirubin level; albumin and
cirrhosis were the accurate independent predictors of OS.
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